BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases 2016; 4(1): 5-19 [PMID: 26798626 DOI: 10.12998/wjcc.v4.i1.5] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 91] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Nautiyal H, Kazmi I, Kaleem M, Afzal M, Ahmad MM, Zafar A, Kaur R. Mechanism of action of drugs used in gastrointestinal diseases. How Synthetic Drugs Work 2023. [DOI: 10.1016/b978-0-323-99855-0.00017-8] [Reference Citation Analysis]
2 Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, Bondari S, Pirscoveanu D, Marginean IC, Iacob GA, Popescu MD, Stanciu M, Mitrut P. The Importance of Accurate Early Diagnosis and Eradication in Helicobacter pylori Infection: Pictorial Summary Review in Children and Adults. Antibiotics (Basel) 2022;12. [PMID: 36671261 DOI: 10.3390/antibiotics12010060] [Reference Citation Analysis]
3 Bisht N, P. Garg A. Helicobacter pylori Gastric Infection: Pathogenesis and Clinical Management. Helicobacter pylori Infection - An Up to Date on the Pathogenic Mechanisms, Diagnosis and Clinical Management [Working Title] 2022. [DOI: 10.5772/intechopen.106783] [Reference Citation Analysis]
4 Metwally M, Ragab R, Abdel Hamid HS, Emara N, Elkholy H. Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study. Infect Drug Resist 2022;15:5905-13. [PMID: 36312439 DOI: 10.2147/IDR.S386082] [Reference Citation Analysis]
5 Correia C, Almeida N, Leal C, Branquinho D, Fernandes A, Gravito-Soares E, Calhau C, Bastos I, Vasconcelos H, Figueiredo P. Single-capsule bismuth-based quadruple therapy as a rescue therapy for Helicobacter pylori eradication. Scand J Gastroenterol 2022;:1-5. [PMID: 36189844 DOI: 10.1080/00365521.2022.2119097] [Reference Citation Analysis]
6 Shao Y, Lin Y, Wang B, Miao M, Ye G. Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021. Helicobacter 2022;27:e12920. [PMID: 35939548 DOI: 10.1111/hel.12920] [Reference Citation Analysis]
7 Nyssen OP, Moreira L, García-morales N, Cano-català A, Puig I, Mégraud F, O’morain C, Gisbert JP. European Registry on Helicobacter pylori Management (Hp-EuReg): Most relevant results for clinical practice. Front Gastroenterol 2022;1. [DOI: 10.3389/fgstr.2022.965982] [Reference Citation Analysis]
8 Souissi S, Makni C, Belhadj Ammar L, Bousnina O, Kallel L. Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study. Helicobacter 2022;27:e12910. [PMID: 35696278 DOI: 10.1111/hel.12910] [Reference Citation Analysis]
9 Attia HG, Albarqi HA, Said IG, Alqahtani O, Raey MAE. Synergistic Effect between Amoxicillin and Zinc Oxide Nanoparticles Reduced by Oak Gall Extract against Helicobacter pylori. Molecules 2022;27:4559. [PMID: 35889432 DOI: 10.3390/molecules27144559] [Reference Citation Analysis]
10 Sharif Z, Mubashir M, Naqvi M, Atique H, Mahmood S, Ullah M. Randomized Clinical Trial on the Efficacy of Triple Therapy Versus Sequential Therapy in Helicobacter pylori Eradication. Cureus 2022. [DOI: 10.7759/cureus.24897] [Reference Citation Analysis]
11 Loharch S, Berlicki Ł. Rational Development of Bacterial Ureases Inhibitors. Chem Rec 2022;:e202200026. [PMID: 35502852 DOI: 10.1002/tcr.202200026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xu M, Zhou J, Heng D, Su X, Onakpa MM, Bai Y, Duan JA, Che CT, Bi H, Zhao M. Quinone Derivatives as Promising Anti-Helicobacter pylori Agents from Aerial Parts of Mitracarpus hirtus. J Nat Prod 2022. [PMID: 35412828 DOI: 10.1021/acs.jnatprod.1c01163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mangiaterra S, Schmidt-küntzel A, Marker L, Di Cerbo A, Piccinini R, Guadagnini D, Turba ME, Berardi S, Galosi L, Preziuso S, Cerquetella M, Rossi G. Effect of a Probiotic Mixture in Captive Cheetahs (Acinonyx Jubatus) with Gastrointestinal Symptoms—A Pilot Study. Animals 2022;12:395. [DOI: 10.3390/ani12030395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Fiori-Duarte AT, de Oliveira Guarnieri JP, de Oliveira Borlot JRP, Lancellotti M, Rodrigues RP, Kitagawa RR, Kawano DF. In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors. Mol Divers 2022. [PMID: 34997872 DOI: 10.1007/s11030-021-10371-8] [Reference Citation Analysis]
15 García-venzor A, Cruz-arenas E, Landero-yoshioka VT, Mandujano-tinoco EA. Genomic Tools in Clinical Epidemiology. Principles of Genetics and Molecular Epidemiology 2022. [DOI: 10.1007/978-3-030-89601-0_3] [Reference Citation Analysis]
16 Fonseca DR, Moura A, Leiro V, Silva-Carvalho R, Estevinho BN, Seabra CL, Henriques PC, Lucena M, Teixeira C, Gomes P, Parreira P, Martins MCL. Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomater 2022;137:186-98. [PMID: 34634508 DOI: 10.1016/j.actbio.2021.09.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Zhao Y, Li Y, Luan Z, Ma C, Yang L, Zhang W, Shi C. Establishment of a TaqMan-MGB probe multiplex real-time PCR system for one-step levofloxacin and clarithromycin resistant Helicobacter pylori detection. J Microbiol Methods 2021;192:106393. [PMID: 34919971 DOI: 10.1016/j.mimet.2021.106393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Kiselev HY, Gorlenko CL, El-taravi YA, Porubayeva EE, Budanova EV. Modern knowledge on pathogenesis, diagnosis and treatment of helicobacter infection. jour 2021. [DOI: 10.31146/1682-8658-ecg-193-9-15-26] [Reference Citation Analysis]
19 Kuang S, Xu J, Chen M, Zhang Y, Shi F, Lu X. The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27944. [PMID: 34964772 DOI: 10.1097/MD.0000000000027944] [Reference Citation Analysis]
20 Azar MH, Jafari Heidarloo M, Majidi H, Paryab S, Garkaz O, Mehryar HR. Elimination of Helicobacter pylori Infection in Patients with Gastrointestinal Problems After Administration of Four-Drug Regimen: A Brief Report. J Arch Mil Med 2021;9. [DOI: 10.5812/jamm.117373] [Reference Citation Analysis]
21 Bala S, Yellamanda KV, Kadari A, Ravinuthala VSU, Kattula B, Singh OV, Gundla R, Addlagatta A. Selective inhibition of Helicobacter pylori methionine aminopeptidase by azaindole hydroxamic acid derivatives: Design, synthesis, in vitro biochemical and structural studies. Bioorg Chem 2021;115:105185. [PMID: 34329997 DOI: 10.1016/j.bioorg.2021.105185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Spósito L, Fortunato GC, de Camargo BAF, Ramos MADS, Souza MPC, Meneguin AB, Bauab TM, Chorilli M. Exploiting drug delivery systems for oral route in the peptic ulcer disease treatment. J Drug Target 2021;:1-19. [PMID: 33729081 DOI: 10.1080/1061186X.2021.1904249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Qaria MA, Qumar S, Sepe LP, Ahmed N. Cholesterol glucosylation-based survival strategy in Helicobacter pylori. Helicobacter 2021;26:e12777. [PMID: 33368895 DOI: 10.1111/hel.12777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Çakir Güney B, Düzenli T, Önal Y, Kaplan M, Tanoğlu A. Favorable effects of close telephone follow-up on Helicobacter pylori eradication success. Anatolian Current Medical Journal 2021;3:10-14. [DOI: 10.38053/acmj.865053] [Reference Citation Analysis]
25 Andreev DN, Kucheryavyy YA, Maev IV. Efficacy of butyric acid inclusion in eradication regimens for <i>Helicobacter pylori </i>infection: a meta-analysis of controlled trials. Terapevticheskii arkhiv 2021;93:158-163. [DOI: 10.26442/00403660.2021.02.200608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Debnath N, Yadav AK. Indigenous Probiotic Lactobacillus Strains to Combat Gastric Pathogen Helicobacter pylori: Microbial Interference Therapy. In: Pawar SV, Rishi P, editors. Probiotic Research in Therapeutics. Singapore: Springer; 2021. pp. 215-30. [DOI: 10.1007/978-981-33-6236-9_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Kipritci Z, Gurol Y, Celik G. Antibiotic Resistance Results of Helicobacter pylori in a University Hospital: Comparison of the Hybridization Test and Real-Time Polymerase Chain Reaction. Int J Microbiol 2020;2020:8853298. [PMID: 33488727 DOI: 10.1155/2020/8853298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Xu M, Zhou J, Zeng L, Xu J, Onakpa MM, Duan J, Che C, Bi H, Zhao M. Pimarane-derived diterpenoids with anti- Helicobacter pylori activity from the tuber of Icacina trichantha. Org Chem Front 2021;8:3014-22. [DOI: 10.1039/d1qo00374g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
29 Chowdhury SK, Misra D, Mandal V. Medicinal Plant-Derived Antimicrobials’ Fight Against Multidrug-Resistant Pathogens. Medicinal and Aromatic Plants 2021. [DOI: 10.1007/978-3-030-58975-2_17] [Reference Citation Analysis]
30 Balash A, Doosti A. Study on the immunogenicity of pcDNA3.1(+)-cagT recombinant vector against Helicobacter pylori in BALB/c mice. J Shahrekord Univ Med Sci 2020;22:159-166. [DOI: 10.34172/jsums.2020.26] [Reference Citation Analysis]
31 Iankov ID, Kurokawa C, Viker K, Robinson SI, Ammayappan A, Panagioti E, Federspiel MJ, Galanis E. Live Attenuated Measles Virus Vaccine Expressing Helicobacter pylori Heat Shock Protein A. Mol Ther Oncolytics 2020;19:136-48. [PMID: 33145397 DOI: 10.1016/j.omto.2020.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tehlan A, Karmakar BC, Paul S, Kumar R, Kaur I, Ghosh A, Mukhopadhyay AK, Dhar SK. Antibacterial action of acriflavine hydrochloride for eradication of the gastric pathogen Helicobacter pylori. FEMS Microbiol Lett 2020;367:fnaa178. [PMID: 33118020 DOI: 10.1093/femsle/fnaa178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Mokhtare M, Nikkhah M, Behnam B, Agah S, Bahardoust M, Masoodi M, Faghihi A. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with Helicobacter pylori infection. Indian J Pharmacol 2020;52:266-71. [PMID: 33078727 DOI: 10.4103/ijp.IJP_719_19] [Reference Citation Analysis]
34 Reihill M, Guazzelli L, Remaut H, Oscarson S. Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori. Molecules 2020;25:E4281. [PMID: 32961972 DOI: 10.3390/molecules25184281] [Reference Citation Analysis]
35 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
36 Fiori-Duarte AT, Rodrigues RP, Kitagawa RR, Kawano DF. Insights into the Design of Inhibitors of the Urease Enzyme - A Major Target for the Treatment of Helicobacter pylori Infections. Curr Med Chem 2020;27:3967-82. [PMID: 30827224 DOI: 10.2174/0929867326666190301143549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
37 Das S, Das MK, Das R, Gehlot V, Mahant S, Mazumder PM, Das S, Falls N, Kumar V. Isolation, characterization of Berberine from Berberis aristata DC for eradication of resistant Helicobacter pylori. Biocatalysis and Agricultural Biotechnology 2020;26:101622. [DOI: 10.1016/j.bcab.2020.101622] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Garabadu D, Singh S, Gautam T. Manilkara hexandra (Roxb.) Dubard Ameliorates Acetic Acid-induced Rat Gastric Ulcer. J Diet Suppl 2021;18:278-92. [PMID: 32449638 DOI: 10.1080/19390211.2020.1770393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
39 Howell AB, Wang L. Potential of cranberry for suppressing Helicobacter pylori, a risk factor for gastric cancer. JBR 2020;10:11-20. [DOI: 10.3233/jbr-180375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Modak AS. 13C breath tests. Breathborne Biomarkers and the Human Volatilome 2020. [DOI: 10.1016/b978-0-12-819967-1.00017-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Ofori EG, Adinortey CA, Bockarie AS, Kyei F, Tagoe EA, Adinortey MB. Helicobacter pylori Infection, Virulence Genes' Distribution and Accompanying Clinical Outcomes: The West Africa Situation. Biomed Res Int 2019;2019:7312908. [PMID: 31886245 DOI: 10.1155/2019/7312908] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
42 Kane-dumbre S, Momin M, Ravikumar P, Khatri R, RK University, Rajkot- 360 028, Gujarat, India. DRUG DELIVERY STRATEGIES FOR HELICOBACTER PYLORI INFECTION MANAGEMENT: AN OVERVIEW. IND DRU 2019;56:7-21. [DOI: 10.53879/id.56.10.11811] [Reference Citation Analysis]
43 de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37): 5578-5589 [PMID: 31602159 DOI: 10.3748/wjg.v25.i37.5578] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 87] [Article Influence: 20.8] [Reference Citation Analysis]
44 Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med 2019;8:E1498. [PMID: 31546909 DOI: 10.3390/jcm8091498] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
45 Min J, Yang Y, Wu Z, Gao W. Robotics in the Gut. Adv Therap 2020;3:1900125. [DOI: 10.1002/adtp.201900125] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
46 González A, Salillas S, Velázquez-Campoy A, Espinosa Angarica V, Fillat MF, Sancho J, Lanas Á. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA. Sci Rep 2019;9:11294. [PMID: 31383920 DOI: 10.1038/s41598-019-47746-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
47 Nim YS, Wong K. The Maturation Pathway of Nickel Urease. Inorganics 2019;7:85. [DOI: 10.3390/inorganics7070085] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
48 Salillas S, Alías M, Michel V, Mahía A, Lucía A, Rodrigues L, Bueno J, Galano-frutos JJ, De Reuse H, Velázquez-campoy A, Carrodeguas JA, Sostres C, Castillo J, Aínsa JA, Díaz-de-villegas MD, Lanas Á, Touati E, Sancho J. Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori -Infected Mice. J Med Chem 2019;62:6102-15. [DOI: 10.1021/acs.jmedchem.9b00355] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
49 Eslami M, Yousefi B, Kokhaei P, Jazayeri Moghadas A, Sadighi Moghadam B, Arabkari V, Niazi Z. Are probiotics useful for therapy of Helicobacter pylori diseases? Comparative Immunology, Microbiology and Infectious Diseases 2019;64:99-108. [DOI: 10.1016/j.cimid.2019.02.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
50 Amin M, Shayesteh AA, Serajian A, Goodarzi H. Assessment of Metronidazole and Clarithromycin Resistance Among Helicobacter pylori Isolates of Ahvaz (Southwest of Iran) During 2015 - 2016 by Phenotypic and Molecular Methods. Jundishapur J Microbiol 2019;In Press. [DOI: 10.5812/jjm.80156] [Reference Citation Analysis]
51 Spósito L, Oda FB, Vieira JH, Carvalho FA, dos Santos Ramos MA, de Castro RC, Crevelin EJ, Crotti AEM, Santos AG, da Silva PB, Chorilli M, Bauab TM. In vitro and in vivo anti-Helicobacter pylori activity of Casearia sylvestris leaf derivatives. Journal of Ethnopharmacology 2019;233:1-12. [DOI: 10.1016/j.jep.2018.12.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
52 Adibzadeh Sereshgi MM, Abdollahpour-Alitappeh M, Mahdavi M, Ranjbar R, Ahmadi K, Taheri RA, Fasihi-Ramandi M. Immunologic balance of regulatory T cell/T helper 17 responses in gastrointestinal infectious diseases: Role of miRNAs. Microb Pathog 2019;131:135-43. [PMID: 30914387 DOI: 10.1016/j.micpath.2019.03.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ghasemian A, Fattahi A, Shokouhi Mostafavi SK, Almarzoqi AH, Memariani M, Ben Braiek O, Yassine HM, Mostafavi NSS, Ahmed MM, Mirforughi SA. Herbal medicine as an auspicious therapeutic approach for the eradication of Helicobacter pylori infection: A concise review. J Cell Physiol. 2019;234:16847-16860. [PMID: 30847906 DOI: 10.1002/jcp.28363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
54 Haydara T, Kabel AM, Elsaka AM. The role of silent helicobacter pylori infection in intragastric ulcers induced by balloon insertion used for management of obesity. Diabetes Metab Syndr 2019;13:116-21. [PMID: 30641681 DOI: 10.1016/j.dsx.2018.08.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Taghavi S, Niknam R, Manafi A. Relationship between Helicobacter Pylori infection and gastric dysplasia: Results from histology of gastric samples in the South of Iran. J Med Sci 2019;39:177. [DOI: 10.4103/jmedsci.jmedsci_205_18] [Reference Citation Analysis]
56 Srivastava A, Srivastava P, Pandey A, Khanna V, Pant A. Phytomedicine. New Look to Phytomedicine. Elsevier; 2019. pp. 625-55. [DOI: 10.1016/b978-0-12-814619-4.00025-2] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Abangah G, Raughani A, Asadollahi P, Asadollahi K. Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment of H. pylori infections resistant to the first line drug regimen among patients referred to Ilam clinics. Gastroenterol Hepatol Bed Bench 2019;12:209-16. [PMID: 31528304] [Reference Citation Analysis]
58 Chakrani Z, Robinson K, Taye B. Association Between ABO Blood Groups and Helicobacter pylori Infection: A Meta-Analysis. Sci Rep 2018;8:17604. [PMID: 30514875 DOI: 10.1038/s41598-018-36006-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
59 Negash M, Wondifraw Baynes H, Geremew D. Helicobacter pylori Infection and Its Risk Factors: A Prospective Cross-Sectional Study in Resource-Limited Settings of Northwest Ethiopia. Can J Infect Dis Med Microbiol 2018;2018:9463710. [PMID: 30420905 DOI: 10.1155/2018/9463710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ram M. R, Teh X, Rajakumar T, Goh KL, Leow AHR, Poh BH, Mariappan V, Shankar EM, Loke MF, Vadivelu J. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy. Journal of Antimicrobial Chemotherapy 2019;74:11-6. [DOI: 10.1093/jac/dky401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
62 Jung JH, Cho IK, Lee CH, Song GG, Lim JH. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Helicobacter pylori Infection. Gut Liver 2018;12:165-72. [PMID: 29212313 DOI: 10.5009/gnl17177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
63 Fernández-Reina A, Urdiales JL, Sánchez-Jiménez F. What We Know and What We Need to Know about Aromatic and Cationic Biogenic Amines in the Gastrointestinal Tract. Foods 2018;7:E145. [PMID: 30181486 DOI: 10.3390/foods7090145] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
64 Hennig B, Petriello MC, Gamble MV, Surh YJ, Kresty LA, Frank N, Rangkadilok N, Ruchirawat M, Suk WA. The role of nutrition in influencing mechanisms involved in environmentally mediated diseases. Rev Environ Health 2018;33:87-97. [PMID: 29381475 DOI: 10.1515/reveh-2017-0038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
65 Al-Eraky DM, Helmy OM, Ragab YM, Abdul-Khalek Z, El-Seidi EA, Ramadan MA. Prevalence of CagA and antimicrobial sensitivity of H. pylori isolates of patients with gastric cancer in Egypt. Infect Agent Cancer. 2018;13:24. [PMID: 30026792 DOI: 10.1186/s13027-018-0198-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
66 Chaudhry A. Pharmacist guidelines and considerations for treating H. pylori. JAPLR 2018;7. [DOI: 10.15406/japlr.2018.07.00222] [Reference Citation Analysis]
67 Tarhini M, Fayyad-kazan M, Fayyad-kazan H, Mokbel M, Nasreddine M, Badran B, Kchour G. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy. Microbial Pathogenesis 2018;117:23-6. [DOI: 10.1016/j.micpath.2018.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
68 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. Gastroenterología y Hepatología (English Edition) 2018;41:145-152. [DOI: 10.1016/j.gastre.2018.03.004] [Reference Citation Analysis]
69 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
70 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
71 Welcome MO. Helicobacter Pylori. Gastrointestinal Physiology 2018. [DOI: 10.1007/978-3-319-91056-7_14] [Reference Citation Analysis]
72 Overbey DM, Jones EL. Acid Peptic Ulcer Disease. Abernathy's Surgical Secrets 2018. [DOI: 10.1016/b978-0-323-47873-1.00047-4] [Reference Citation Analysis]
73 Serajian A. PCR-RFLP Detection of Point Mutations in 23sr RNA Gene Responsible for Clarithromycin Resistance in Helicobacter pylori Isolates of Ahvaz, Iran. IJMBOA 2017;2. [DOI: 10.15406/ijmboa.2017.02.00038] [Reference Citation Analysis]
74 Zhang L, Hu P. Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients. Clin Interv Aging 2017;12:673-8. [PMID: 28442897 DOI: 10.2147/CIA.S127009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017;11:196-208. [PMID: 28274108 DOI: 10.5009/gnl16126] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 15.2] [Reference Citation Analysis]
76 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
77 Gan D, Xu A, Du H, Ye Y. Chinese Classical Formula Sijunzi Decoction and Chronic Atrophic Gastritis: Evidence for Treatment Approach? Evid Based Complement Alternat Med 2017;2017:9012929. [PMID: 29138645 DOI: 10.1155/2017/9012929] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
78 Subramani R, Narayanasamy M, Feussner KD. Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens. 3 Biotech 2017;7:172. [PMID: 28660459 DOI: 10.1007/s13205-017-0848-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 13.0] [Reference Citation Analysis]
79 Sharma C, Singh BP, Thakur N, Gulati S, Gupta S, Mishra SK, Panwar H. Antibacterial effects of Lactobacillus isolates of curd and human milk origin against food-borne and human pathogens. 3 Biotech 2017;7:31. [PMID: 28401466 DOI: 10.1007/s13205-016-0591-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
80 Frugis S, Czeczko NG, Malafaia O, Parada AA, Poletti PB, Secchi TF, Degiovani M, Rampanazzo-Neto A, D Agostino MD. PREVALENCE OF HELICOBACTER PYLORI TEN YEARS AGO COMPARED TO THE CURRENT PREVALENCE IN PATIENTS UNDERGOING UPPER ENDOSCOPY. Arq Bras Cir Dig 2016;29:151-4. [PMID: 27759776 DOI: 10.1590/0102-6720201600030006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
81 Mccarthy TR, Patel AA, Anderson PE, Anderson DM. Bacterial Pathogens. Biological Safety 2016. [DOI: 10.1128/9781555819637.ch8] [Reference Citation Analysis]
82 Lee KY, Lee BJ. Solution NMR studies on Helicobacter pylori proteins for antibiotic target discovery. Expert Opin Drug Discov 2016;11:681-93. [PMID: 27216839 DOI: 10.1080/17460441.2016.1189411] [Reference Citation Analysis]
83 Mottaghi B, Emami MH, Riahi P, Fahim A, Rahimi H, Mohammadi R. Candida colonization of the esophagus and gastric mucosa; a comparison of patients taking proton pump inhibitors and those taking histamine receptor antagonist drugs. Gastroenterol Hepatol Bed Bench 2021;14:349-55. [PMID: 34659663] [Reference Citation Analysis]
84 Ebrahimpour S, Esmaeili H, Ghadimi R. Food bioactive componts, a possible adjuvant for H.pylori eradication. Caspian J Intern Med 2017;8:131-2. [PMID: 28702157 DOI: 10.22088/cjim.8.2.131] [Cited by in F6Publishing: 2] [Reference Citation Analysis]